Xeris Biopharma Holdings (XERS) Non-Current Debt (2020 - 2026)

Xeris Biopharma Holdings' Non-Current Debt history runs 7 years deep, the most recent figure standing at $221.2 million for Q1 2026.

• Quarterly Non-Current Debt fell 3.72% year-over-year to $221.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $221.2 million (down 3.72% YoY) and the FY2025 annual result came in at $220.3 million, down 5.07% from the prior year.
• Non-Current Debt was $221.2 million for Q1 2026 at Xeris Biopharma Holdings, roughly flat from $220.3 million in the prior quarter.
• Across five years, Non-Current Debt topped out at $232.1 million in Q4 2024 and bottomed at $137.6 million in Q1 2022.
• A 5-year average of $198.6 million and a median of $216.2 million in 2024 frame the typical range for Non-Current Debt.
• Annual changes were most pronounced in 2022 — Non-Current Debt jumped 112.42% — and 2025, when it declined 5.14%.
• Xeris Biopharma Holdings' Non-Current Debt stood at $187.1 million in 2022, then advanced by 2.06% to $190.9 million in 2023, then climbed by 21.57% to $232.1 million in 2024, then retreated by 5.07% to $220.3 million in 2025, then grew by 0.4% to $221.2 million in 2026.
• Business Quant data shows XERS's Non-Current Debt at $221.2 million in Q1 2026, $220.3 million in Q4 2025, and $219.5 million in Q3 2025.